Skip to Content
Merck
CN
  • The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice.

The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice.

Nature communications (2020-05-20)
Shota Yoshida, Hironori Nakagami, Hiroki Hayashi, Yuka Ikeda, Jiao Sun, Akiko Tenma, Hideki Tomioka, Tomohiro Kawano, Munehisa Shimamura, Ryuichi Morishita, Hiromi Rakugi
ABSTRACT

Senotherapy targeting for senescent cells is designed to attenuate age-related dysfunction. Senescent T cells, defined as CD4+ CD44high CD62Llow PD-1+ CD153+ cells, accumulate in visceral adipose tissues (VAT) in obese individuals. Here, we show the long-lasting effect of using CD153 vaccination to remove senescent T cells from high-fat diet (HFD)-induced obese C57BL/6J mice. We administered a CD153 peptide-KLH (keyhole limpet hemocyanin) conjugate vaccine with Alhydrogel (CD153-Alum) or CpG oligodeoxynucleotide (ODN) 1585 (CD153-CpG) and confirmed an increase in anti-CD153 antibody levels that was sustained for several months. After being fed a HFD for 10-11 weeks, adipose senescent T cell accumulation was significantly reduced in the VAT of CD153-CpG-vaccinated mice, accompanied by glucose tolerance and insulin resistance. A complement-dependent cytotoxicity (CDC) assay indicated that the mouse IgG2 antibody produced in the CD153-CpG-vaccinated mice successfully reduced the number of senescent T cells. The CD153-CpG vaccine is an optional tool for senolytic therapy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Octoclothepin maleate salt, solid
Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O111:B4, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
Resiquimod, ≥98% (HPLC)